Research programme: cancer and autoimmune disorder therapeutics - BroadenBio
Latest Information Update: 09 Jun 2023
At a glance
- Originator BroadenBio
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Solid tumours
Most Recent Events
- 30 May 2023 Early research in Autoimmune disorders in China (unspecified route) as of May 2023 (BroadenBio pipeline, May 2023)
- 30 May 2023 Early research in Solid tumours in China (unspecified route) as of May 2023 (BroadenBio pipeline, May 2023)